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ABSTRACT The PA-X protein of influenza A virus has roles in host cell shutoff and
viral pathogenesis. While most strains are predicted to encode PA-X, strain-
dependent variations in activity have been noted. We found that PA-X protein from
the A/PR/8/34 (PR8) strain had significantly lower repressive activity against cellular
gene expression than PA-X proteins from the avian strains A/turkey/England/50-
92/91 (H5N1) (T/E) and A/chicken/Rostock/34 (H7N1). Loss of normal PA-X expres-
sion, either by mutation of the frameshift site or by truncating the X open reading
frame (ORF), had little effect on the infectious virus titer of PR8 or PR8 7:1 reassor-
tants with T/E segment 3 grown in embryonated hens’ eggs. However, in both virus
backgrounds, mutation of PA-X led to decreased embryo mortality and lower overall
pathology, effects that were more pronounced in the PR8 strain than in the T/E re-
assortant, despite the low shutoff activity of the PR8 PA-X. Purified PA-X mutant vi-
rus particles displayed an increased ratio of hemagglutinin (HA) to nucleoprotein
(NP) and M1 compared to values for their wild-type (WT) counterparts, suggesting
altered virion composition. When the PA-X gene was mutated in the background of
poorly growing PR8 6:2 vaccine reassortant analogues containing the HA and neur-
aminidase (NA) segments from H1N1 2009 pandemic viruses or from an avian H7N3
strain, HA yield increased up to 2-fold. This suggests that the PR8 PA-X protein may
harbor a function unrelated to host cell shutoff and that disruption of the PA-X
gene has the potential to improve the HA yield of vaccine viruses.
IMPORTANCE Influenza A virus is a widespread pathogen that affects both humans
and a variety of animal species, causing regular epidemics and sporadic pandemics, with
major public health and economic consequences. A better understanding of virus biol-
ogy is therefore important. The primary control measure is vaccination, which for hu-
mans mostly relies on antigens produced in eggs from PR8-based viruses bearing the
glycoprotein genes of interest. However, not all reassortants replicate well enough to
supply sufficient virus antigen for demand. The significance of our research lies in identi-
fying that mutation of the PA-X gene in the PR8 strain of virus can improve antigen
yield, potentially by decreasing the pathogenicity of the virus in embryonated eggs.
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Influenza epidemics occur most years as the viruses undergo antigenic drift. InfluenzaA viruses (IAV) and influenza B viruses cause seasonal human influenza, but IAV poses
an additional risk of zoonotic infection, with the potential of a host switch and the
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generation of pandemic influenza virus. The 1918 Spanish flu pandemic was by far the
worst, resulting in 40 to 100 million deaths worldwide (1), while the 2009 swine flu
pandemic caused an estimated 200,000 deaths worldwide (2).
IAV contains eight genomic segments encoding at least 10 proteins. Six genomic
segments (segments 1, 2, 3, 5, 7, and 8) encode the eight core internal proteins PB2,
PB1, PA, nucleoprotein (NP), M1, NS1, and NS2, as well as the ion channel M2. These
segments can also encode a variety of accessory proteins known to influence patho-
genesis and virulence (reviewed in references 3 and 4). Segments 4 and 6 encode the
two surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), respectively (5,
6), and virus strains are divided into subtypes according to the antigenicity of these
proteins.
Vaccination is the primary public health measure to reduce the impact of influenza
epidemics and pandemics, principally using inactivated viruses chosen to antigenically
match the currently circulating virus strains or newly emerging viruses of pandemic
concern. However, before efficient vaccine production can commence, high-yielding
candidate vaccine viruses (CVVs) need to be prepared. Seasonal CVVs are widely
produced by classical reassortment. This process involves coinfecting embryonated
hens’ eggs with the vaccine virus along with a high-yielding donor virus adapted to
growth in eggs (most commonly the A/Puerto Rico/8/34 strain, or PR8). The highest-
yielding viruses that contain the glycoproteins of the vaccine virus are then selected.
Recombinant influenza viruses are also made by reverse genetics (RG) (7–9), which
relies on the transfection of cells with plasmids engineered to express both viral
genomic RNA and proteins from each of the eight segments and, hence, to initiate virus
production; the resultant virus is subsequently amplified in eggs. When RG CVVs are
made, typically the six segments encoding core proteins (backbone) are derived from
the donor strain whereas the two segments encoding the antigens are derived from the
vaccine virus. Classical reassortment has the advantage that it allows the fittest natural
variant to be selected, but the process can be time-consuming. In the case of a
pandemic, large quantities of vaccine must be made available quickly. Moreover, RG is
the only viable method for production of CVVs for potentially pandemic highly patho-
genic avian influenza viruses since it allows removal of genetic determinants of high
pathogenicity in the virus genome as vaccines are manufactured in biosafety level 2
laboratories. A limited number of donor strains for IAV vaccine manufacture currently
exist. Although PR8 is widely used, reassortant viruses based on it do not always grow
sufficiently well for efficient vaccine manufacture. In the case of the 2009 H1N1
pandemic (pdm09), vaccine viruses grew poorly in eggs compared with growth of
those for previous seasonal H1N1 isolates (10), resulting in manufacturers struggling to
meet demand. Thus, there is a clear need for new reagents and methods for IAV
production, particularly for a response to a pandemic.
In recent years, several approaches have been employed to improve antigen yield
of candidate vaccine viruses made by reverse genetics. These have involved empirical
testing and selection of PR8 variants (11, 12), as well as targeted approaches such as
making chimeric genes containing promoter and packaging signal regions of PR8 while
encoding the ectodomain of the CVV glycoprotein genes (13–21) or introducing a
wild-type (WT) virus-derived segment 2 (21–29). Our approach was to manipulate
expression of an accessory protein virulence factor, PA-X (30). Segment 3, encoding PA
as the primary gene product, also expresses PA-X by low-level ribosomal shifting into
a1 open reading frame (ORF), termed the X ORF (Fig. 1) (30). PA-X is a 29-kDa protein
that contains the N-terminal endonuclease domain of PA and, in most isolates, a
61-amino-acid (aa) C terminus from the X ORF (30–32). It has roles in shutting off host
cell protein synthesis and, at the whole-animal level, modulating the immune response
(30, 33). Loss of PA-X expression has been shown to be associated with increased
virulence in mice for 1918 H1N1, H5N1, and also pdm09 and classical swine influenza
H1N1 strains, as well as in chickens and ducks infected with a highly pathogenic H5N1
virus (30, 34–40). However, in other circumstances, such as avian H9N2 viruses (40) or,
in some cases, A(H1N1)pdm09 viruses (37, 41), mutation of PA-X resulted in reduced
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pathogenicity in mice. Similarly, a swine influenza H1N2 virus (42) lacking PA-X showed
reduced pathogenicity in pigs. Moreover, PA-X activity in repressing cellular gene
expression is strain dependent (33, 34, 40, 43), with laboratory-adapted viruses such as
A/WSN/33 (WSN) showing lower levels of activity (33). Here, we show that although the
PR8 PA-X polypeptide has low shutoff activity, removing its expression decreases the
pathogenicity of the virus in the chicken embryo model. Moreover, we found that, for
certain poorly growing CVV mimics, ablating PA-X expression improved HA yield from
embryonated eggs up to 2-fold. In no case did loss of PA-X appear to be detrimental
to the growth of CVVs, making it a potential candidate mutation for incorporation into
the PR8 CVV donor backbone.
(This article was submitted to an online preprint archive [44].)
RESULTS
The PR8 virus strain PA-X has relatively low shutoff activity. Previous work has
noted variation in apparent activity of PA-X proteins from different strains of virus, with
the laboratory-adapted strain WSN showing lower activity than many other strains (33).
Reexamination of evidence concerning a postulated proteolytic activity of PA (43)
suggested that lower PA-X activity might also be a feature of the PR8 strain. To test this,
the ability of PR8 segment 3 gene products to inhibit cellular gene expression was
compared to that of two avian virus-derived PA segments (from A/chicken/Rostock/34
[H7N1; FPV] and A/turkey/England/50-92/91 [H5N1; T/E]. Avian QT-35 (Japanese quail
fibrosarcoma) cells were cotransfected with a consistent amount of a plasmid encoding
luciferase under the control of a constitutive RNA polymerase II promoter (pRL) and
increasing amounts of the IAV cDNAs (in pHW2000-based RG plasmids) or, as a negative
control, with the maximum amount of the empty pHW2000 vector. Luciferase expres-
sion was measured 48 h later and expressed as a percentage of the amount obtained
from pRL-only transfections. Transfection of a 4-fold excess of empty pHW2000 vector
over the luciferase reporter plasmid had no significant effect on luciferase expression,
whereas cotransfection of the same amount of either the FPV or T/E segments sup-
pressed activity to around 10% of the control level (Fig. 2A). Titration of the FPV and T/E
plasmids gave a clear dose-response relationship, giving estimated 50% effective
concentration (EC50) values of 24 1.1 ng and 32 1.1 ng, respectively. In contrast, the
maximum amount of the PR8 plasmid inhibited luciferase expression by only around
30%, and an EC50 value could not be calculated, indicating a lower ability to repress
cellular gene expression. Similarly, low inhibitory activity of the PR8 segment 3 was
seen in a variety of other mammalian cell lines (data not shown), suggesting that it was
an intrinsic feature of the viral gene rather than a host- or cell-type-specific outcome.
Several studies have shown the X ORF to be important in the host cell shutoff
function and virulence of PA-X (37, 45–47). To further explore the influence of X ORF
sequences on virus strain-specific host cell shutoff, mutations were constructed in
segment 3 in which PA-X expression was either hindered (via mutation of the frameshift
[FS] site) or altered by the insertion of premature termination codons (PTC1 to PTC4;
silent in the PA ORF) such that C-terminally truncated forms of PA-X would be
expressed (Fig. 1). QT-35 cells were cotransfected with the pRL plasmid and a fixed
FIG 1 Mutational strategies used to alter IAV PA-X expression. The schematic diagram shows mutations
in segment 3: a mutation at the frameshift (FS) site to generate a PA-X null virus, a mutation in the X ORF
so that segment 3 expresses C-terminally truncated versions of PA-X (PTCs 1 to 4; size of products
indicated), or removal of cytosine 598 (delC598) to place the X ORF in frame with PA such that only PA-X
is expressed.
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amount of WT, FS, or PTC plasmid, and luciferase expression was measured 48 h later.
As before, the WT FPV and T/E PA-X proteins reduced luciferase activity by approxi-
mately 5- to 10-fold, while WT PR8 PA-X had no significant effect (Fig. 2B). Introducing
the FS mutation into both the PR8 and T/E segment 3s significantly increased luciferase
activity relative to that of the WT construct. Truncation of the PR8 PA-X to 225 aa or less
(PTC mutations 1 to 3) significantly improved shutoff activity although not to the levels
seen with the WT avian virus polypeptides, while the PTC4 truncation had no effect. In
contrast, none of the PTC mutations significantly affected activity of the T/E PA-X
although there was a trend toward increased activity from the PTC2, PTC3, and PTC4
truncations.
Low activity could be due to decreased expression and/or decreased activity of
PA-X. To examine this, expression levels of the low-activity PR8 and high-activity FPV
PA-X constructs were compared by in vitro translation (IVT) reactions in rabbit reticu-
locyte lysate. Translation of segment 3s from both PR8 and FPV produced both
full-length PA and similar quantities of a minor polypeptide species of the expected size
for PA-X, whose abundance decreased after addition of the FS mutation or whose
electrophoretic mobility was altered in stepwise fashion after C-terminal truncation
with the mutations of PTC1 to PTC4 (Fig. 3A). This suggested that differences in shutoff
potential were not linked to intrinsic differences in PA-X protein synthesis. To confirm
the identity of the PR8 in vitro-translated polypeptides, immunoprecipitations of IVT
products with serum raised against either the N-terminal domain of PA or an X
ORF-derived polypeptide or preimmune sera (30) were performed (Fig. 3B). WT PA-X
was clearly visible in samples immunoprecipitated with anti-PA-X and anti-PA-N but not
with the preimmune serum, where it comigrated with the product from the delC598
plasmid, a construct in which cytosine 598 of segment 3 (the nucleotide skipped during
the PA-X frameshifting event [48]) had been deleted to put the X ORF into the same
reading frame as the N-terminal PA domain (Fig. 3B, lanes 2 and 7). In contrast, only
background amounts of protein were precipitated from the FS IVT (Fig. 3B, lane 3).
Faster-migrating polypeptide products from the PTC3 and PTC4 plasmids showed
similar reactivities to WT PA-X (Fig. 3B, lanes 5 and 6) whereas the product of the PTC1
plasmid was precipitated only by anti-PA-N (lane 4), as expected because of the loss of
the epitope used to raise the PA-X antiserum (Fig. 1). Overall, therefore, the PR8 PA-X
polypeptide possessed lower shutoff activity than two avian virus PA-X polypeptides
FIG 2 Virus strain-dependent variation in PA-X-mediated host cell shutoff activity. PA-X-mediated
inhibition of cellular RNA polymerase II-driven gene expression in QT-35 cells. (A) Cells were cotrans-
fected with 100 ng of pRL plasmid constitutively expressing Renilla luciferase and a dilution series of the
indicated segment 3 pHW2000 plasmids or with a fixed amount of the empty pHW2000 vector (VOC).
Luciferase (luc) activity was measured 48 h later and plotted as a percentage of the value for the pRL-only
sample. Dose-inhibition curves were fitted using GraphPad Prism software. Data are means  standard
deviations of two independent experiments, each performed in triplicate. (B) Cells were cotransfected
with 100 ng of pRL plasmid and 400 ng of effector pHW2000 plasmids expressing segment 3 products.
Luciferase activity was measured 48 h later and plotted as a percentage of the value for a pHW2000
vector-only control. Data are the means  standard deviations from two independent experiments
performed in duplicate. Dashed lines indicate groups of statistical tests (against the left-hand bar in each
case) as assessed by Dunnett’s test (*, P  0.05; **, P 0.01; ***, P 0.001; ns, not significant).
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despite comparable expression levels in vitro, and its activity could be modulated by
mutation of the X ORF.
Loss of PA-X expression results in significantly less pathogenicity in chick
embryos without affecting virus replication. In order to further characterize the role
of PA-X as a virulence determinant, we tested the panel of high- and low-activity
mutants in the chicken embryo pathogenicity model. Embryonated hens’ eggs were
infected with PR8-based viruses containing either PR8 or T/E WT or mutant segment 3s,
and embryo viability was monitored at 2 days postinfection (p.i.) by candling. Both WT
PR8 and the WT 7:1 reassortant with the T/E segment 3 viruses had killed over 50% of
the embryos by this point (Fig. 4A and B). Truncation of PA-X by the PTC mutations led
to small improvements in embryo survival although none of the differences were
statistically significant. However, embryo lethality was significantly reduced to below
20% following infection with the PR8 FS virus compared to the lethality of PR8 WT virus.
A similar reduction in lethality was seen for the T/E FS virus although the difference was
not statistically significant. This reduction in embryo pathogenicity following ablation
of PA-X expression suggested potential utility as a targeted mutation in the PR8
backbone used to make CVVs. Accordingly, to characterize the effects of mutating PR8
PA-X over the period used for vaccine manufacture, embryo survival was monitored
daily for 72 h. Eggs infected with WT PR8 showed 45% embryo survival at 2 days p.i.,
and all embryos were dead by day 3 (Fig. 4C). However, the PR8 FS-infected eggs
showed a statistically significant improvement in survival compared to that of the WT,
with 80% and 30% survival at days 2 and 3, respectively. Embryos infected with PR8
expressing the C-terminally truncated PTC1 form of PA-X showed an intermediate
survival phenotype, with 60% and 20% survival at days 2 and 3, respectively.
To further assess the effects of mutating PA-X, the chicken embryos were examined
for gross pathology. WT PR8 infection resulted in smaller, more fragile embryos with
diffuse reddening, interpreted as hemorrhages (Fig. 4D). In comparison, the PA-X null
FS mutant-infected embryos remained intact and were visibly larger and less red. To
quantitate these observations, embryos were scored blind for gross pathology. Taking
uninfected embryos as a baseline, it was clear that WT PR8 virus as well as the PA-X
truncation mutants induced severe changes to the embryos (Fig. 4E). In contrast, the
PA-X null FS mutant caused significantly less pathology. The WT 7:1 T/E reassortant
virus gave less overt pathology than WT PR8, but, again, reducing PA-X expression
through the FS mutation further reduced damage to the embryos (Fig. 4F). Similar
trends in pathology were also seen with 7:1 PR8 reassortant viruses containing either
WT or FS mutant versions of FPV segment 3 (data not shown).
Examination of hematoxylin and eosin (H&E)-stained sections through the embryos
revealed pathology in numerous organs, including the brain, liver, and kidney (Fig. 5).
FIG 3 Expression of PA-X polypeptides in vitro. Aliquots of rabbit reticulocyte lysate supplemented with
[35S]methionine were programmed with WT or mutated (as indicated) segment 3 plasmids or with empty
plasmid vector (VOC), and the resulting radiolabeled polypeptides were visualized by SDS-PAGE and
autoradiography before (A) or after (B) immunoprecipitation with the indicated antisera. Arrowheads in
panel A indicate full-length PA-X while molecular mass (kDa) markers are shown on the left.
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In the brain of embryos infected with WT virus, there was marked rarefaction of the
neuropil, few neurons were identifiable, and there was accumulation of red blood cells
(Fig. 5C). In the liver of embryos infected with WT virus, the hepatic cords were
disorganized, and the hepatocytes were often separated by large pools of red blood
cells (Fig. 5D). In the kidney of embryos infected with WT virus, tubules were often lined
by degenerate epithelial cells (characterized by loss of cellular detail) (Fig. 5E). In all
cases, the pathology noted in WT virus-infected embryos was also present in the FS
virus-infected embryos but with reduced severity. Thus, overall, disruption of PA-X
expression in PR8 resulted in significantly less pathogenicity in chick embryos.
Reduced pathogenicity in vivo following loss of PA-X expression could be due to a
replication deficiency of the virus although the viruses replicated equivalently in
mammalian MDCK cells (data not shown). To test if replication did differ in ovo,
infectious virus titers were obtained (by plaque titration on MDCK cells) from the
FIG 4 Effect of PA-X mutations in a chicken embryo pathogenicity model. Groups of 5 to 6 embryonated
hens’ eggs were infected with 1,000 PFU of the indicated viruses, and embryo viability was determined
by candling at 2 days p. i. (A and B). Data are plotted as means  standard errors of the means of the
percent embryo lethality from 3 to 4 independent experiments. Horizontal bars indicate statistical
significance (*, P 0.05) as assessed by Dunnett’s test. (C) Infected eggs were monitored daily for embryo
viability, and survival was plotted versus time. Data are from three independent experiments with 5 to
10 eggs per experiment. Statistical significance between WT and FS viruses (**, P  0.01) was assessed
by a log rank (Mantel-Cox) test. (D to F) From the experiments described in panels A and B, embryos were
imaged and scored blind by two observers as follows: 0, normal; 1, intact but bloody; 2, small, damaged,
and with severe hemorrhages. (E and F) Data are the averages  standard error of the means of the
pathology scores from 3 to 4 independent experiments. The horizontal bar indicates statistical signifi-
cance (***, P  0.001) as assessed by Dunnett’s test.
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FIG 5 Histopathology of chick embryos following infection with PR8 viruses. Embryonated hens’ eggs were
infected with segment 3 WT or mutant viruses or mock infected. At 2 days p.i. embryos were fixed, sectioned,
and stained with H&E before imaging with a NanoZoomer XR instrument (Hamamatsu) using bright-field
settings. Representative pictures are shown as indicated. Scale bars: 5mm (A), 2.5mm (B), 1mm (C and D, upper
row), 500m (E, upper row) 100m (C to E, lower row). C, cerebral hemisphere; H, heart; L, liver; PCT, proximal
convoluted tubule; CD, collecting duct; HP, hepatocytes; BV, blood vessel.
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allantoic fluid of embryonated hens’ eggs infected with the panels of PR8 and T/E
viruses at 2 days p.i. However, there were no significant differences in titers between
either PR8 or T/E WT and PA-X mutant viruses (Fig. 6A and B). Since the reduced
pathogenicity phenotype in ovo on loss of PA-X expression was more pronounced for
viruses with PR8 segment 3 than for those with the T/E gene, embryos from PR8 WT and
segment 3 mutant-infected eggs were harvested at 2 days p.i., washed, and macerated,
and virus titers from the homogenates were determined. Titers from embryos infected
with the PR8 FS and PTC4 viruses were slightly (less than 2-fold) reduced compared to
titers of embryos infected with PR8 WT virus (Fig. 6C), but overall there were no
significant differences in titers between the viruses. To see if there were differences in
virus localization in tissues between PR8 WT and FS viruses, immunohistochemistry was
performed on chicken embryo sections to detect viral NP as a marker of infected cells.
NP-positive cells were seen in blood vessels throughout the head and body of both PR8
WT- and FS-infected embryos; liver, heart and kidney are shown as representatives (Fig.
6D), indicating that the circulatory system had been infected. However, there were no
FIG 6 Effects of mutating PA-X expression on virus replication in chick embryos. Groups of 5 to 6 embryonated hens’ eggs were infected with
the indicated viruses, and at 2 days p.i., virus titers were determined by plaque assay from allantoic fluid (A and B) or from washed and macerated
chick embryos (C). Graphs represent the means standard errors of the mean s from three (A and B) or two to four (C) independent experiments.
Titers of mutant viruses were not significantly different from the WT virus titer (Dunnett’s test). (D) Embryos were fixed at 2 days p.i., sectioned,
and stained for IAV NP and DNA before imaging was performed using a NanoZoomer XR instrument (Hamamatsu) on fluorescence settings.
Representative images of liver, heart, and kidney are shown. Scale bar, 100 m. Red, NP; blue, DAPI.
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clear differences in virus localization between embryos infected with the WT and those
infected with FS viruses.
Overall, therefore, the loss of PA-X expression reduced IAV pathogenicity in chick
embryos, as assessed by mortality curves and both gross and histopathological exam-
ination of embryo bodies. This reduced pathogenicity did not appear to correlate with
reduced replication or with altered distribution of the virus in ovo.
Ablating PA-X expression alters virion composition. Other viruses encode host
control proteins with mRNA endonuclease activity, including the SOX protein of murine
gammaherpesvirus MHV68, whose expression has been shown also to modulate virion
composition (49). Also, egg-grown IAV titer and HA yield do not always exactly match,
with certain problematic CVVs containing smaller amounts of HA per virion (16, 50, 51).
Accordingly, we compared the relative quantities of virion structural proteins between
PA-X-expressing and PA-X null viruses. Two pairs of viruses were tested: either an
entirely PR8-based virus or a 7:1 reassortant of PR8 with FPV segment 3, both with and
without the FS mutation. Viruses were grown in eggs as before and purified from
allantoic fluid by density gradient ultracentrifugation before polypeptides were sepa-
rated by SDS-PAGE and visualized by staining with Coomassie blue. To ensure that
overall differences in protein loading did not bias the results, 3-fold dilutions of the
samples were analyzed. From the gels, the major virion components of both WT and FS
virus preparations could be distinguished: NP, the two cleaved forms of hemagglutinin,
HA1 and HA2, the matrix protein, M1, and in lower abundance, the polymerase proteins
(Fig. 7A and B, lanes 4 to 9). In contrast, only trace polypeptides were present in
FIG 7 Virion composition of WT or FS mutant viruses. Embryonated hens’ eggs were infected with WT or segment 3 mutant
viruses or mock infected. (A and B) At 2 days p.i., virus was purified from allantoic fluid by sucrose density gradient
ultracentrifugation, and 3-fold serial dilutions were analyzed by SDS-PAGE on 10% polyacrylamide gels and staining with
Coomassie blue. (C and D) For PR8 and FPV, respectively, the ratios of HA1/NP and HA2/M1 were determined by densitometry
of SDS-PAGE gels. Scatter plots with the means and standard errors of the means of six measurements from three independent
experiments using two independently rescued virus stocks are shown. Horizontal bars indicate statistical significance (*, P 
0.05) as assessed by paired t test.
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similarly purified samples from uninfected allantoic fluid (Fig. 7A and B, lanes 1 to 3).
Densitometry was used to assess the relative viral protein contents of the viruses. The
two most heavily loaded lanes (where band intensities were sufficient for accurate
measurement) were quantified, and average HA1/NP and HA2/M1 ratios were calcu-
lated. When the data from three independent experiments were examined in aggre-
gate by scatter plot, a statistically significant increase in the average quantity of HA1
relative to that of NP was evident for both PR8 and the FPV reassortant FS viruses of
1.4-fold and 1.6-fold, respectively, compared to the level of the WT (Fig. 7C and D).
The ratio of HA2/M1 was also significantly increased in the PR8 FS virus (1.2- fold
greater than that of the WT), and a similar but nonsignificant increase was seen for the
FPV virus pair. These data are consistent with the hypothesis that PA-X expression
modulates virion composition.
Ablating PA-X expression increases HA yield of CVVs bearing pdm09 glyco-
proteins. The reduced pathogenicity and corresponding longer embryo survival time
induced by the PR8 FS mutant in ovo, coupled with evident modulation of virion
composition in favor of HA content, suggested a strategy to increase overall antigen
yields for PR8-based CVVs. Therefore, the effect of incorporating the PA-X FS mutation
into CVV mimics containing glycoproteins of different IAV subtypes was examined.
Reasoning that a benefit might be most apparent for a poor-yielding strain, 6:2 CVV
mimics containing the glycoprotein genes from the A(H1N1)pdm09 vaccine strain,
A/California/07/2009 (Cal7), with the six internal genes from PR8, with or without the FS
mutation in segment 3, were generated. Growth of these viruses in embryonated hens’
eggs was then assessed by inoculating eggs with either 100, 1,000, or 10,000 PFU per
egg (modeling the empirical approach used in vaccine manufacture to find the optimal
inoculation dose) and measuring the HA titer at 3 days p.i. Both viruses grew best at an
inoculation dose of 100 PFU/egg, but final yield was both relatively low (as expected,
64 hemagglutinating units [HAU]/50 l) and insensitive to input dose, with average
titers varying less than 2-fold across the 100-fold range of inocula (Fig. 8A). However,
at each dose, the 6:2 FS virus gave a higher titer (on average, 1.6-fold) than the parental
6:2 reassortant. In order to assess HA yield between the WT and FS viruses on a larger
scale, comparable to that used by WHO Essential Regulatory Laboratories (ERLs) such as
the National Institute for Biological Standards and Control (NIBSC), United Kingdom, 20
eggs per virus were infected at a single inoculation dose. In this experiment, the
average HA titer of the FS virus was over 3 times higher than that of the WT 6:2 virus
(Fig. 8B). To further determine the consistency of these results, HA titer yields were
assessed from two independently rescued reverse genetics stocks of the Cal7 6:2 CVV
mimics, with or without the PR8 PA-X gene, as well as from another 6:2 CVV mimic
bearing the glycoproteins from the A/England/195/2009 (Eng195) A(H1N1)pdm09
strain. HA yield from different stocks was assessed in independent repeats of both
small-scale (5 eggs for each of three different inoculation doses, taking data from the
dose that gave maximum yield) and large-scale (20 eggs per single dose of virus)
experiments. Examination of the average HA titers showed considerable variation
between results of independent experiments (Fig. 8C). However, when titers were
plotted as paired data points, it was obvious that in every experiment, the FS viruses
gave a higher yield than the parental 6:2 reassortant, and, on average, there were 2.7-
and 3.8-fold higher HA titers with the segment 3 FS mutation for Cal7 and Eng195,
respectively (Table 1).
To directly assess HA protein yield, viruses were partially purified by ultracentrifu-
gation of pooled allantoic fluid through 30% sucrose cushions. Protein content was
analyzed by SDS-PAGE and Coomassie staining, either before or after treatment with
peptide-N-glycosidase F (PNGase F) to remove glycosylation from HA and NA. Both
virus preparations gave polypeptide profiles that were clearly different from those of
uninfected allantoic fluid processed in parallel, with obvious NP and M1 staining, as well
from other polypeptide species of less certain origin (Fig. 8D). Overall protein recovery
was higher in the FS virus than in the WT reassortant virus (Fig. 8D, compare lanes 3 and
4 with lanes 5 and 6), but the poor yields of these viruses made unambiguous
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identification of the HA polypeptide difficult. However, PNGase F treatment led to the
appearance of a defined protein band migrating at around 40 kDa that probably
represented deglycosylated HA1, and this was present in appreciably higher quantities
in the 6:2 FS preparation (Fig. 8D, compare lanes 4 and 6). Therefore, equivalent
amounts of glycosylated or deglycosylated samples from the Cal7 WT and FS reassor-
tants were analyzed by SDS-PAGE and Western blotting using anti-pdm09 HA serum.
The Western blot gave a clear readout for HA1 content, confirmed the mobility shift
upon deglycosylation, and showed increased amounts of HA1 in the 6:2 FS samples
(Fig. 8D, lower panel). Quantitative measurements of the deglycosylated samples
showed that the 6:2 FS virus gave a 1.9-fold-greater HA1 yield than the WT reassortant.
To test the reproducibility of this finding, HA1 yield was assessed by densitometry of
deglycosylated HA1 following SDS-PAGE and Western blotting for partially purified
virus from nine independent experiments with the Cal7 and Eng195 reassortants. When
results were examined as paired observations, it was evident that in 8 of the 9
experiments, the FS viruses gave greater HA yields than the parental virus, with only
one experiment producing a smaller amount (Fig. 8E). In one large-scale experiment,
FIG 8 Effect of the PA-X FS mutation on HA yield of A(H1N1)pdm09 CVV mimics. (A to C) Embryonated
hens’ eggs were infected as indicated, and HA titers in allantoic fluid were measured at 3 days p.i. for groups
of 5 (A) or 20 eggs (B) per condition. Scatter plots of titers from individual eggs with means and standard
errors of the means are shown. (***, P  0.001; assessed by unpaired t test). Average HA titers from groups
of eggs inoculated at the infection dose which gave maximum yield are shown as paired observations (C).
Statistical significance was assessed by a paired t test (*, P  0.05; n  9). (D and E) Allantoic fluid was
clarified, and virus was pelleted by ultracentrifugation through 30% sucrose pads. Equal volumes of
resuspended virus pellets were separated by SDS-PAGE on a 12% polyacrylamide gel and visualized by
staining with Coomassie blue (upper panel) or Western blotting for HA1 (lower panel) with () or without
() prior treatment with PNGase F (D). Molecular mass (kDa) markers and specific polypeptides are labeled.
Deglycosylated HA1 yield was quantified by densitometry of the Western blots (E). Data points represent
eight independent experiments using three independently rescued RG virus stocks shown as paired
observations (**, P 0.01, n 8; as assessed by paired t test). Circles represent Cal7, and squares represent
Eng195 CVV mimics.
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the HA1 yield of 6:2 FS was approximately 20-fold higher than that of its 6:2 counter-
part. However, in all other experiments, the 6:2 FS virus gave between 1.5- and 3-fold
increases in HA1 yield compared with the yield of the 6:2 virus. When the outlier was
discounted (as possibly resulting from an artefactually low recovery for the WT sample),
average HA1 yield from the other eight experiments showed 1.9- and 2.4-fold improve-
ments with the segment 3 FS mutation for Cal7 and Eng195, respectively (Table 1).
The HA yield of CVVs with pdm09 glycoproteins has been shown to be improved by
engineering chimeric HA genes which contain signal peptide and transmembrane
domain/cytoplasmic tail sequences from PR8 HA and the antigenic region of the HA
gene from Cal7 (19, 20). To test if these gains were additive with those seen with the
FS mutation, we introduced the NIBRG-119 construct, which is a segment 4 with the
ectodomain coding region of Cal7 HA and all other sequences (3= and 5= noncoding
regions, signal peptide, transmembrane domain, and cytoplasmic tail) from PR8 (19)
into 6:2 CVV mimics with the WT A(H1N1)pdm09 NA gene and a PR8 backbone with or
without the PA-X mutation. Viruses bearing the NIBRG-119 HA did not agglutinate
chicken red blood cells (data not shown), so HA yield from eggs was assessed by
SDS-PAGE and Western blotting of partially purified virus. Chimeric HA viruses contain-
ing the FS backbone showed an average HA yield improvement of 1.5-fold compared
to the level of the WT backbone counterpart across independent small- and large-scale
experiments (Table 1). Thus, the FS mutation is compatible with other rational strate-
gies for increasing egg-grown reverse genetics vaccines.
Following on from this, several pairs of CVV mimics were made with glycoproteins
from different IAV strains with either WT or FS mutant PR8 segment 3. These included
viruses with glycoproteins of potentially pandemic strains, such as the highly patho-
genic avian virus A/turkey/Turkey/1/2005 (H5N1) and low-pathogenic avian strains
A/mallard/Netherlands/12/2000 (H7N3), A/chicken/Pakistan/UDL-01/2008 (H9N2), and
A/mallard/Netherlands/10/99 (H1N1), as well as the human H3N2 strain A/Hong Kong/
1/68 and an early seasonal H3N2 isolate, A/Udorn/307/72 (Table 1). HA yield in eggs
was assessed from both the small-scale and large-scale experimental conditions de-
scribed earlier by measuring HA titer and HA1 yield from partially purified virus
particles. In general, the results of the two techniques were in agreement (Table 1).
Ablating PA-X expression moderately improved HA1 yields of some of the CVVs tested:
1.5-fold for the avian H7N3 strain A/mallard/Netherlands/12/2000 and 1.3-fold for the
human H3N2 A/Udorn/307/72 strain. Other CVVs showed smaller or effectively no
increases. However, in no case did ablation of PA-X appear to be detrimental to the
growth of CVVs.
DISCUSSION
Here, we show that ablating expression of PA-X resulted in reduced pathogenicity
in the chicken embryo model despite the PR8 PA-X protein having relatively low host
cell shutoff activity compared to that of PA-X from other IAV strains. Although loss of
PA-X expression had no effect on infectious titers in eggs, subtle differences in virion
composition were observed, and, more importantly, the HA yield from poor-growing
6:2 reassortant vaccine analogues containing the HA and NA segments from
A(H1N1)pdm09 strains was significantly improved.
The majority of studies examining the effect of loss of PA-X expression on IAV
pathogenicity have used mice as the experimental system. As discussed above, in most
cases, the outcome has been increased virulence (30, 34–40), but several studies have
found the opposite effect, with PA-X deficiency reducing pathogenicity in mice (37, 41,
42). In adult bird challenge systems using chickens and ducks infected with a highly
pathogenic H5N1 virus, abrogating PA-X expression caused increased virulence (35). In
our infection model of embryonated hens’ eggs, loss of PA-X expression markedly
reduced the pathogenicity in chick embryos. Thus, like PB1-F2, another trans-frame-
encoded IAV accessory protein (52), the impact of PA-X expression on viral pathoge-
nicity seems to vary according to both host and virus strains but not in a fashion that
can simply be correlated with mammalian or avian settings.
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In previous studies, changes in virulence phenotypes following loss of PA-X expres-
sion have been associated with its host cell shutoff function. In the virus strains used,
whether from high-pathogenicity or low-pathogenicity IAV strains, the PA-X polypep-
tides were shown to significantly affect host cell gene expression. Here, despite PR8
PA-X failing to repress cellular gene expression, a strong phenotypic effect was seen in
chicken embryos following loss of PA-X expression. Furthermore, these effects on
pathogenicity were more pronounced in an otherwise WT PR8 virus than in a 7:1
reassortant with segment 3 from the highly pathogenic H5N1 avian influenza T/E strain,
which encodes a PA-X with strong host cell shutoff activity. This lack of correlation
between repression of cellular gene expression in avian cells and phenotypic effects in
chicken embryos suggests that the PR8 PA-X protein may harbor a function unrelated
to host cell shutoff. The PR8 PA-X protein has been proposed to inhibit stress granule
formation but via a mechanism linked to its endonuclease activity and therefore
presumably reflecting shutoff activity (53). Alternatively, it could be that the PR8 PA-X
polypeptide exhibits a repressive function only in specific cell types, such as those of
the chorioallantoic membrane (the primary site of virus replication in eggs) or the
chicken embryo itself. However, since we found low shutoff activity from PA-X in a
variety of cells from different species and, conversely, no great cell specificity for
high-activity PA-X polypeptides (data not shown), we do not favor this hypothesis.
Several studies have found that sequences in the X ORF make positive contributions
to the shutoff activity of PA-X (30, 37, 39, 46, 47). In contrast, here we found that for
both PR8 and T/E strains of the polypeptide, removal of X ORF sequences actually
increased shutoff activity compared to the level with the WT polypeptide. The effect
was relatively modest and, in the case of PR8, did not confer equivalent activity to the
full-length avian virus PA-X polypeptides (Fig. 2B). A similar outcome of greater
inhibition from a truncated PA-X polypeptide was seen with a triple reassortant swine
influenza virus (42), suggesting that the X ORF can harbor negative as well as positive
regulatory polymorphisms.
In some but not all studies, effects of PA-X mutations on viral pathogenicity have
been associated with differences in virus replication in vivo. While Jagger et al. (30) did
not attribute the increased virulence in mice upon loss of 1918 H1N1 PA-X to virus
replication, Gao and colleagues found that increased virulence in mice on loss of H5N1
PA-X was associated with increased titers of PA-X-deficient (ΔPA-X) viruses in the lungs,
brains, and blood of infected mice (34, 39). Similarly, Hu et al. found that increased
virulence in chicken, ducks, and mice of a ΔPA-X H5N1 virus was associated with
increased virus titers in the host (35). Given the postulated role of PA-X-mediated
repression of cellular gene expression in controlling host responses to infection, it is
reasonable to hypothesize that these differing outcomes reflect the variable interplay
between host and virus that is well known to tip in favor of one or the other depending
on exact circumstance (54). Our present study, where loss of a PA-X protein with little
apparent ability to modulate host gene expression had no significant effect on virus
titers in allantoic fluid or the chick embryos themselves but nevertheless reduced
pathogenicity, do not support this hypothesis. However, differences in progeny virion
composition in the form of altered ratios of HA to NP and M1 between WT and FS
viruses were seen. This may differentially affect their abilities to infect specific cell types
as the amount of virus receptor varies between different tissue types and is a known
determinant of tissue tropism of influenza viruses (reviewed in references 55 and 56).
Our findings have direct implications for HA yield of vaccine viruses in eggs. Ablating
PA-X expression did not affect yield from eggs of high-growth viruses such as PR8 or
from 6:2 reassortant CVV mimics containing glycoproteins of human H3N2 strains or
from potentially pandemic low-pathogenicity avian H9N2 or H1N1 viruses. However,
mutation of the PR8 PA-X gene in the background of a CVV analogue containing the HA
and NA segments from poor-growing strains, such as A(H1N1)pdm09 viruses or a
potentially pandemic avian H7N3 isolate, increased HA yield by around 2-fold. The
mechanism of improved yield of certain virus subtypes but not others upon loss of PA-X
expression is unclear. Other investigators have found that mutating the FS site of PR8
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PA-X has subtle effects on viral protein expression in vitro, including lower levels of M1
(46), perhaps explaining the changes in the HA-to-M1 ratio we see. Beneficial outcomes
to HA yield may be apparent only in low-yielding strains where perhaps viral rather
than cellular factors are limiting. Alternatively, changes in virion composition between
WT and FS viruses could result in subtype-/strain-specific effects depending on the
balance between HA and NA activities (57). Whatever the mechanism, in no case was
loss of PA-X expression detrimental to the yield of CVVs when the HA yield of a wide
range of different influenza A subtypes/strains was assessed. This approach of modi-
fying the PR8 donor backbone therefore potentially supplies a universal approach that
can be applied to all CVVs that is additive with, but without the need for, generation
and validation of subtype-/strain-specific constructs, as is required for strategies based
on altering the glycoprotein genes. This could be beneficial to improve antigen yield in
a pandemic setting where manufacturers are required to produce large amounts of
vaccine quickly.
MATERIALS AND METHODS
Cell lines and plasmids. Human embryonic kidney (293T) cells, Madin-Darby canine kidney epithelial
cells (MDCK), and MDCK-SIAT1 (stably transfected with the cDNA of human 2,6-sialtransferase) cells (58)
were obtained from the Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United
Kingdom. QT-35 (Japanese quail fibrosarcoma) cells (59) were obtained from Laurence Tiley, University
of Cambridge. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) containing
10% (vol/vol) fetal bovine serum (FBS), 100 U/ml penicillin-streptomycin, and 100 U/ml GlutaMAX with
1 mg/ml Geneticin as a selection marker for the SIAT cells. Infection was carried out in serum-free DMEM
containing 100 U/ml penicillin-streptomycin, 100 U/ml GlutaMAX, and 0.14% (wt/vol) bovine serum
albumin (BSA). Cells were incubated at 37°C in 5% CO2. Reverse genetics plasmids were kindly provided
by Ron Fouchier (A/Puerto Rico/8/34) (60), Wendy Barclay (A/England/195/2009 [61] and A/turkey/
England/50-92/91 [62]), John McCauley (A/California/07/2009) (63), Laurence Tiley (A/mallard/Nether-
lands/10/1999) (64), Robert Lamb (A/Udorn/307/72) (65)), Earl Brown (A/Hong Kong/1/68) (66)), and
Munir Iqbal (A/chicken/Pakistan/UDL-01/2008) (67). RG plasmids for A/mallard/Netherlands/12/2000
(NIBRG-60) and A/turkey/Turkey/1/2005 (NIBRG-23; with the multibasic cleavage site removed) (68) were
made by amplifying HA and NA genes by PCR from cDNA clones available within the NIBSC and cloning
them in a pHW2000 vector using BsmB1 restriction sites. A plasmid containing the Renilla luciferase gene
behind the simian virus 40 early promoter (pRL) was supplied by Promega Ltd.
Antibodies and sera. Primary antibodies used were the following: rabbit polyclonal antibody
anti-HA for swine H1 (Ab91641; Abcam), rabbit polyclonal anti-HA for H7N7 A/chicken/MD/MINHMA/
2004 (IT-003-008; Immune Tech Ltd.), mouse monoclonal anti-HA for H5N1 (8D2 and Ab82455; Abcam),
laboratory-made rabbit polyclonal anti-NP (2915) (69), anti-PA residues 16 to 213 (expressed as a fusion
protein with -galactosidase (70), anti-puromycin mouse monoclonal antibody (MABE343; Millipore),
rabbit anti-PR8 PA-X peptide (residues 211 to 225) antibody (30), and anti-alpha-tubulin rat monoclonal
antibody (MCA77G; Serotec). Secondary antibodies used were the following: for immunofluorescence,
Alexa Fluor donkey anti-rabbit IgG 488 or 594 conjugates (Invitrogen); for immunohistochemistry, goat
anti-mouse horseradish peroxidase (172-1011; Bio-Rad) and goat anti-rabbit horseradish peroxidase
(172-1019; Bio-Rad); for Western blotting, donkey anti-rabbit IgG Dylight 800 or Alexa Fluor 680-
conjugated donkey anti-mouse IgG (LiCor Biosciences).
Site-directed mutagenesis. A QuikChange Lightning site-directed mutagenesis kit (Stratagene) was
used according to the manufacturer’s instructions. Primers used for site-directed mutagenesis of the
segment 3 gene were designed using the primer design tool from Agilent technologies. The strategies
used to disrupt the frameshift (FS) site as well as to generate C-terminally truncated versions of PA-X via
PTCs were as described previously (30) (the cited study used the PTC1 construct).
Protein analyses. Coupled in vitro transcription-translation reactions were carried out in rabbit
reticulocyte lysate supplemented with [35S]methionine using a Promega TNT system according to the
manufacturer’s instructions. SDS-PAGE followed by autoradiography was performed according to stan-
dard procedures. Immunoprecipitations were performed as previously described (71). Transfection-based
reporter assays to assess host cell shutoff by PA-X (described previously [30]) were performed by
cotransfecting QT-35 cells with a reporter plasmid containing the Renilla luciferase gene along with
pHW2000 plasmids expressing the appropriate segment 3 genes with or without the desired PA-X
mutations. At 48 h posttransfection, cells were lysed, and luciferase activity was measured on a Promega
GloMax 96-well microplate luminometer using the Promega Renilla luciferase system.
Reverse genetics rescue of viruses. All viruses used in this study were made by reverse genetics.
293T cells were transfected with eight pHW2000 plasmids, each encoding one of the influenza virus
segments using Lipofectamine 2000 (Invitrogen). Cells were incubated for 6 h posttransfection before
medium was replaced with DMEM serum-free virus growth medium. At 2 days posttransfection,
0.5 g/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Sigma) was added to cells. Cell
culture supernatants were harvested at 3 days posttransfection. 293T cell culture supernatants were
clarified and used to infect 10- to 11 day-old embryonated hens’ eggs. At 3 days p.i., eggs were chilled
overnight, and virus stocks were partially sequenced to confirm identity.
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RNA extraction, RT-PCR, and sequence analysis. Viral RNA extractions were performed using a
QIAamp viral RNA minikit with on-column DNase digestion (Qiagen). Reverse transcription used the
influenza A virus Uni12 primer (AGCAAAAGCAGG) using a Verso cDNA kit (Thermo Scientific). PCRs were
performed using Pfu Ultra II fusion 145 HS polymerase (Stratagene) or Taq polymerase (Invitrogen)
according to the manufacturers’ protocols. PCR products were purified for sequencing by Illustra GFX
PCR DNA and a Gel Band Purification kit (GE Healthcare). Primers and purified DNA were sent to GATC
Biotech for Sanger sequencing (Lightrun method). Sequences were analyzed using DNAstar software.
Virus titration. Plaque assays, assays of the 50% tissue culture infective dose (TCID50), and hemag-
glutination assays were performed according to standard methods (72). MDCK or MDCK-SIAT cells were
used for infectious virus titration, and infectious foci were visualized by either toluidine blue or
immunostaining for viral NP and revealed using a tetramethyl benzidine (TMB) substrate.
Virus purification and analysis. Allantoic fluid was clarified by centrifugation twice at 6,500  g for
10 min. Virus was then partially purified by ultracentrifugation at 128,000  g for 1.5 h at 4°C through
a 30% sucrose cushion. For further purification, virus pellets were resuspended in phosphate-buffered
saline (PBS), loaded onto 15 to 60% sucrose-PBS density gradients, and centrifuged at 210,000  g for
40 min at 4°C. Virus bands were extracted from gradients, and virus was pelleted by ultracentrifugation
at 128,000  g for 1.5 h at 4°C. Pellets were resuspended in PBS, and aliquots were treated with
N-glycosidase F (New England Biolabs), according to the manufacturer’s protocol. Virus pellets were lysed
in Laemmli sample buffer and separated by SDS-PAGE on 10% or 12% polyacrylamide gels under
reducing conditions. Protein bands were visualized by Coomassie blue staining (Imperial protein stain;
Thermo Scientific) or detected by immunostaining in Western blotting. Coomassie-stained gels were
scanned, and bands were quantified using ImageJ software. Western blots were scanned on a LiCor
Odyssey infrared imaging system, version 1.2, after they were stained with the appropriate antibodies,
and bands were quantified using Image Studio Lite software (Odyssey).
Chicken embryo pathogenesis model. Ten-day old embryonated hens’ eggs were inoculated via
the allantoic cavity route with 1,000 PFU in 100 l per egg or were mock (serum-free medium only)
infected. Embryo viability was subsequently determined by examination of veins lining the shell (which
collapse on death) and embryo movement (for a few minutes). At 2 to 3 days p.i. (depending on
experiment), embryos were killed by chilling, washed several times in PBS, and then scored blind for
overt pathology by two observers in each experiment. Embryo scoring was as follows: 0, normal; 1, intact
but with dispersed hemorrhages; 2, small, fragile embryo with dispersed hemorrhages. For histology,
embryos were decapitated, washed several times in PBS, imaged, and fixed for several days in 4%
formalin in PBS. Two embryos per virus condition were sectioned longitudinally and mounted onto
paraffin wax. Tissue sections were cut and mounted onto slides and stained with hematoxylin and eosin
(H&E) by the Easter Bush Pathology Service. Further sections were examined by immunohistofluores-
cence performed for influenza virus NP (63). Sections were deparaffinized and rehydrated, and heat-
induced antigen retrieval was performed using sodium citrate buffer (10 mM sodium citrate, 0.05%
Tween 20, pH 6.0). Sections were stained with anti-NP antibody followed by an Alexa Fluor-conjugated
secondary antibody. Preimmune bleed serum was also used to confirm specificity of staining by anti-NP
antibody. Sections were mounted using ProLong Gold antifade reagent containing 4=,6-diamidino-2-
phenylindole (DAPI) (Invitrogen). Stained tissue sections were scanned using a NanoZoomer XR instru-
ment (Hamamatsu) using bright-field or fluorescence settings. Images were analyzed using the NDP view,
version 2.3, software (Hamamatsu).
Graphs and statistical analyses. All graphs were plotted, and statistical analyses (Mantel-Cox test,
t tests, and Dunnett’s and Tukey’s tests as part of one-way analysis of variance [ANOVA]) were performed
using GraphPad Prism software.
ACKNOWLEDGMENTS
We thank Francesco Gubinelli, Carolyn Nicolson, and Ruth Harvey at the Influenza
Resource Centre, National Institute for Biological Standards and Control, United King-
dom, for their support during experiments performed in their lab and the staff at the
Easter Bush Pathology service for pathology support, Bob Fleming and José Pereira for
imaging assistance, and Liliane Chung and Marlynne Quigg-Nicol for technical advice.
This work was funded in part with Federal funds from the Office of the Assistant
Secretary for Preparedness and Response, Biomedical Advanced Research and Devel-
opment Authority, under contract number HHSO100201300005C (to O.G.E. and P.D.),
by a grant from the UK Department of Health’s Policy Research Program (NIBSC
Regulatory Science Research Unit), grant number 044/0069 (to O.G.E.), and the Intra-
mural Research Program of the National Institute of Allergy and Infectious Diseases
(NIAID) (to J.K.T.), as well as Institute Strategic Program Grants (BB/J01446X/1 and
BB/P013740/1) from the Biotechnology and Biological Sciences Research Council
(BBSRC) to P.D., P.M.B., L.V., and H.M.W. B.W.J., P.D., and J.K.T. are also grateful for the
support of the NIH-Oxford-Cambridge Research Scholars program.
The views expressed in the publication are those of the author(s) and not necessarily
those of the NHS, the NIHR, the Department of Health, “arms-length” bodies, or other
government departments.
Hussain et al. Journal of Virology
January 2019 Volume 93 Issue 2 e01551-18 jvi.asm.org 16
 o
n
 January 8, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
REFERENCES
1. Johnson NPAS, Mueller J. 2002. Updating the accounts: global mortality
of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 76:
105–115. https://doi.org/10.1353/bhm.2002.0022.
2. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng P-Y,
Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB,
Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R,
Montgomery JM, Mølbak K, Pebody R, Presanis AM, Razuri H, Steens A,
Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson M-A. 2012.
Estimated global mortality associated with the first 12 months of 2009
pandemic influenza A H1N1 virus circulation: a modelling study. Lancet
Infect Dis. 12:687–695. https://doi.org/10.1016/S1473-3099(12)70121-4.
3. Khaperskyy DA, McCormick C. 2015. Timing is everything: coordinated
control of host shutoff by influenza A virus NS1 and PA-X proteins. J Virol
89:6528–6531. https://doi.org/10.1128/JVI.00386-15.
4. Vasin AV, Temkina OA, Egorov VV, Klotchenko SA, Plotnikova MA, Kiselev
OI. 2014. Molecular mechanisms enhancing the proteome of influenza A
viruses: an overview of recently discovered proteins. Virus Res 185:
53–63. https://doi.org/10.1016/j.virusres.2014.03.015.
5. Palese P, Schulman JL. 1976. Mapping of the influenza virus genome:
identification of the hemagglutinin and the neuraminidase genes. Proc
Natl Acad Sci U S A 73:2142–2146. https://doi.org/10.1073/pnas.73.6
.2142.
6. Ritchey MB, Palese P, Schulman JL. 1976. Mapping of the influenza virus
genome. III. Identification of genes coding for nucleoprotein, membrane
protein, and nonstructural protein. J Virol 20:307–313. https://jvi.asm
.org/content/20/1/307.long.
7. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M,
Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. 1999. Generation
of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci
U S A 96:9345–9350. https://doi.org/10.1073/pnas.96.16.9345.
8. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A
DNA transfection system for generation of influenza A virus from eight
plasmids. Proc Natl Acad Sci U S A 97:6108–6113. https://doi.org/10
.1073/pnas.100133697.
9. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-
Sastre A. 1999. Rescue of influenza A virus from recombinant DNA. J Virol
73:9679–9682. https://jvi.asm.org/content/73/11/9679.
10. Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K,
Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J,
Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E,
Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O,
Xie H, Li X, Lin Z, Ye Z, Chen L-M, O’Neill E, Balish A, Lipatov AS, Guo Z,
Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey
TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO. 2011. The development
of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29:
1836–1843. https://doi.org/10.1016/j.vaccine.2010.12.044.
11. Johnson A, Chen LM, Winne E, Santana W, Metcalfe MG, Mateu-Petit G,
Ridenour C, Hossain MJ, Villanueva J, Zaki SR, Williams TL, Cox NJ, Barr JR,
Donis RO. 2015. Identification of influenza A/PR/8/34 donor viruses impart-
ing high hemagglutinin yields to candidate vaccine viruses in eggs. PLoS
One 10:e0128982. https://doi.org/10.1371/journal.pone.0128982.
12. Ping J, Lopes TJ, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher
EA, Neumann G, Kawaoka Y. 2015. Development of high-yield influenza
A virus vaccine viruses. Nat Commun 6:8148. https://doi.org/10.1038/
ncomms9148.
13. Barman S, Krylov PS, Turner JC, Franks J, Webster RG, Husain M, Webby
RJ. 2017. Manipulation of neuraminidase packaging signals and hemag-
glutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influ-
enza vaccine virus yield in eggs. Vaccine 35:1424–1430. https://doi.org/
10.1016/j.vaccine.2017.01.061.
14. Adamo JE, Liu T, Schmeisser F, Ye Z. 2009. Optimizing viral protein yield
of influenza virus strain A/Vietnam/1203/2004 by modification of the
neuraminidase gene. J Virol 83:4023–4029. https://doi.org/10.1128/JVI
.02391-08.
15. Pan W, Dong Z, Meng W, Zhang W, Li T, Li C, Zhang B, Chen L. 2012.
Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1)
growth with the neuraminidase packaging sequence from A/Puerto
Rico/8/34. Hum Vaccin Immunother 8:252–259. https://doi.org/10.4161/
hv.18468.
16. Jing X, Phy K, Li X, Ye Z. 2012. Increased hemagglutinin content in a
reassortant 2009 pandemic H1N1 influenza virus with chimeric neur-
aminidase containing donor A/Puerto Rico/8/34 virus transmembrane
and stalk domains. Vaccine 30:4144–4152. https://doi.org/10.1016/j
.vaccine.2012.04.073.
17. Harvey R, Nicolson C, Johnson RE, Guilfoyle KA, Major DL, Robertson JS,
Engelhardt OG. 2010. Improved haemagglutinin antigen content in
H5N1 candidate vaccine viruses with chimeric haemagglutinin mole-
cules. Vaccine 28:8008–8014. https://doi.org/10.1016/j.vaccine.2010.09
.006.
18. Harvey R, Johnson RE, MacLellan-Gibson K, Robertson JS, Engelhardt OG.
2014. A promoter mutation in the haemagglutinin segment of influenza
A virus generates an effective candidate live attenuated vaccine. Influ-
enza Other Respir Viruses 8:605–612. https://doi.org/10.1111/irv.12274.
19. Harvey R, Guilfoyle KA, Roseby S, Robertson JS, Engelhardt OG. 2011.
Improved antigen yield in pandemic H1N1 (2009) candidate vaccine
viruses with chimeric hemagglutinin molecules. J Virol 85:6086–6090.
https://doi.org/10.1128/JVI.00096-11.
20. Medina J, Boukhebza H, De Saint Jean A, Sodoyer R, Legastelois I, Moste
C. 2015. Optimization of influenza A vaccine virus by reverse genetic
using chimeric HA and NA genes with an extended PR8 backbone.
Vaccine 33:4221–4227. https://doi.org/10.1016/j.vaccine.2015.06.112.
21. Plant EP, Ye Z. 2015. Chimeric neuraminidase and mutant PB1 gene
constellation improves growth and yield of H5N1 vaccine candidate
virus. J Gen Virol 96:752–755. https://doi.org/10.1099/jgv.0.000025.
22. Plant EP, Liu TM, Xie H, Ye Z. 2012. Mutations to A/Puerto Rico/8/34 PB1
gene improves seasonal reassortant influenza A virus growth kinetics.
Vaccine 31:207–212. https://doi.org/10.1016/j.vaccine.2012.10.060.
23. Cobbin JC, Verity EE, Gilbertson BP, Rockman SP, Brown LE. 2013. The
source of the PB1 gene in influenza vaccine reassortants selectively
alters the hemagglutinin content of the resulting seed virus. J Virol
87:5577–5585. https://doi.org/10.1128/JVI.02856-12.
24. Cobbin JC, Ong C, Verity E, Gilbertson BP, Rockman SP, Brown LE. 2014.
Influenza virus PB1 and neuraminidase gene segments can cosegregate
during vaccine reassortment driven by interactions in the PB1 coding
region. J Virol 88:8971–8980. https://doi.org/10.1128/JVI.01022-14.
25. Wanitchang A, Kramyu J, Jongkaewwattana A. 2010. Enhancement of
reverse genetics-derived swine-origin H1N1 influenza virus seed vaccine
growth by inclusion of indigenous polymerase PB1 protein. Virus Res
147:145–148. https://doi.org/10.1016/j.virusres.2009.10.010.
26. Gomila RC, Suphaphiphat P, Judge C, Spencer T, Ferrari A, Wen Y,
Palladino G, Dormitzer PR, Mason PW. 2013. Improving influenza virus
backbones by including terminal regions of MDCK-adapted strains on
hemagglutinin and neuraminidase gene segments. Vaccine 31:
4736–4743. https://doi.org/10.1016/j.vaccine.2013.08.026.
27. Giria M, Santos L, Louro J, Rebelo de Andrade H. 2016. Reverse genetics
vaccine seeds for influenza: proof of concept in the source of PB1 as a
determinant factor in virus growth and antigen yield. Virology 496:
21–27. https://doi.org/10.1016/j.virol.2016.05.015.
28. Mostafa A, Kanrai P, Ziebuhr J, Pleschka S. 2016. The PB1 segment of an
influenza A virus H1N1 2009pdm isolate enhances the replication efficiency
of specific influenza vaccine strains in cell culture and embryonated eggs. J
Gen Virol 97:620–631. https://doi.org/10.1099/jgv.0.000390.
29. Gilbertson B, Zheng T, Gerber M, Printz-Schweigert A, Ong C, Marquet R,
Isel C, Rockman S, Brown L. 2016. Influenza NA and PB1 gene segments
interact during the formation of viral progeny: localization of the bind-
ing region within the PB1 gene. Viruses 8:238. https://doi.org/10.3390/
v8080238.
30. Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL,
Schwartzman LM, Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins
JF, Firth AE, Taubenberger JK, Digard P. 2012. An overlapping protein-
coding region in influenza A virus segment 3 modulates the host response.
Science 337:199–204. https://doi.org/10.1126/science.1222213.
31. Shi M, Jagger BW, Wise HM, Digard P, Holmes EC, Taubenberger JK.
2012. Evolutionary conservation of the PA-X open reading frame in
segment 3 of influenza A virus. J Virol 86:12411–12413. https://doi.org/
10.1128/JVI.01677-12.
32. Yewdell JW, Ince WL. 2012. Virology. Frameshifting to PA-X influenza.
Science 337:164–165. https://doi.org/10.1126/science.1225539.
33. Desmet EA, Bussey KA, Stone R, Takimoto T. 2013. Identification of the
N-terminal domain of the influenza virus PA responsible for the sup-
pression of host protein synthesis. J Virol 87:3108–3118. https://doi.org/
10.1128/JVI.02826-12.
Influenza a Virus PA-X and Pathogenicity in Hens’ Eggs Journal of Virology
January 2019 Volume 93 Issue 2 e01551-18 jvi.asm.org 17
 o
n
 January 8, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
34. Gao H, Sun Y, Hu J, Qi L, Wang J, Xiong X, Wang Y, He Q, Lin Y, Kong W,
Seng LG, Sun H, Pu J, Chang KC, Liu X, Liu J. 2015. The contribution of
PA-X to the virulence of pandemic 2009 H1N1 and highly pathogenic
H5N1 avian influenza viruses. Sci Rep 5:8262. https://doi.org/10.1038/
srep08262.
35. Hu J, Mo Y, Wang X, Gu M, Hu Z, Zhong L, Wu Q, Hao X, Hu S, Liu W, Liu
H, Liu X, Liu X. 2015. PA-X decreases the pathogenicity of highly patho-
genic H5N1 influenza A virus in avian species by inhibiting virus repli-
cation and host response. J Virol 89:4126–4142. https://doi.org/10.1128/
JVI.02132-14.
36. Hayashi T, MacDonald LA, Takimoto T. 2015. Influenza A virus protein
PA-X contributes to viral growth and suppression of the host antiviral
and immune responses. J Virol 89:6442–6452. https://doi.org/10.1128/
JVI.00319-15.
37. Lee J, Yu H, Li Y, Ma J, Lang Y, Duff M, Henningson J, Liu Q, Li Y, Nagy
A, Bawa B, Li Z, Tong G, Richt JA, Ma W. 2017. Impacts of different
expressions of PA-X protein on 2009 pandemic H1N1 virus replication,
pathogenicity and host immune responses. Virology 504:25–35. https://
doi.org/10.1016/j.virol.2017.01.015.
38. Hu J, Mo Y, Gao Z, Wang X, Gu M, Liang Y, Cheng X, Hu S, Liu W, Liu H,
Chen S, Liu X, Peng D, Liu X. 2016. PA-X-associated early alleviation of
the acute lung injury contributes to the attenuation of a highly patho-
genic H5N1 avian influenza virus in mice. Med Microbiol Immunol
205:381–395. https://doi.org/10.1007/s00430-016-0461-2.
39. Gao H, Sun H, Hu J, Qi L, Wang J, Xiong X, Wang Y, He Q, Lin Y, Kong W,
Seng LG, Pu J, Chang KC, Liu X, Liu J, Sun Y. 2015. Twenty amino acids
at the C-terminus of PA-X are associated with increased influenza A virus
replication and pathogenicity. J Gen Virol 96:2036–2049. https://doi.org/
10.1099/vir.0.000143.
40. Gao H, Xu G, Sun Y, Qi L, Wang J, Kong W, Sun H, Pu J, Chang KC, Liu J.
2015. PA-X is a virulence factor in avian H9N2 influenza virus. J Gen Virol
96:2587–2594. https://doi.org/10.1099/jgv.0.000232.
41. Nogales A, Rodriguez L, DeDiego ML, Topham DJ, Martinez-Sobrido L.
2017. Interplay of PA-X and NS1 proteins in replication and pathogenesis
of a temperature-sensitive 2009 pandemic H1N1 influenza A virus. J Virol
91:e00720-17.
42. Xu G, Zhang X, Liu Q, Bing G, Hu Z, Sun H, Xiong X, Jiang M, He Q, Wang
Y, Pu J, Guo X, Yang H, Liu J, Sun Y. 2017. PA-X protein contributes to
virulence of triple-reassortant H1N2 influenza virus by suppressing early
immune responses in swine. Virology 508:45–53. https://doi.org/10
.1016/j.virol.2017.05.002.
43. Naffakh N, Massin P, van der Werf S. 2001. The transcription/replication
activity of the polymerase of influenza A viruses is not correlated with
the level of proteolysis induced by the PA subunit. Virology 285:
244–252. https://doi.org/10.1006/viro.2001.0956.
44. Hussain S, Turnbull ML, Wise HM, Jagger BW, Beard PM, Kovacikova K,
Taubenberger JK, Vervelde L, Engelhardt OG, Digard P. 2018. Mutation of
influenza A virus PA-X decreases pathogenicity in chicken embryos and
can increase the yield of reassortant candidate vaccine viruses. bioRxiv
https://doi.org/10.1101/409375.
45. Hayashi T, Chaimayo C, McGuinness J, Takimoto T, Abdel-Wahab M.
2016. Critical role of the PA-X C-terminal domain of influenza A virus in
its subcellular localization and shutoff activity. J Virol 90:7131–7141.
https://doi.org/10.1128/JVI.00954-16.
46. Khaperskyy DA, Schmaling S, Larkins-Ford J, McCormick C, Gaglia MM.
2016. Selective degradation of host RNA polymerase II transcripts by
influenza A virus PA-X host shutoff protein. PLoS Pathog 12:e1005427.
https://doi.org/10.1371/journal.ppat.1005427.
47. Oishi K, Yamayoshi S, Kawaoka Y. 2015. Mapping of a region of the PA-X
protein of influenza A virus that is important for its shutoff activity. J
Virol 89:8661–8665. https://doi.org/10.1128/JVI.01132-15.
48. Firth AE, Jagger BW, Wise HM, Nelson CC, Parsawar K, Wills NM,
Napthine S, Taubenberger JK, Digard P, Atkins JF. 2012. Ribosomal
frameshifting used in influenza A virus expression occurs within the
sequence UCC_UUU_CGU and is in the 1 direction. Open Biol
2:120109. https://doi.org/10.1098/rsob.120109.
49. Abernathy E, Clyde K, Yeasmin R, Krug LT, Burlingame A, Coscoy L,
Glaunsinger B. 2014. Gammaherpesviral gene expression and virion com-
position are broadly controlled by accelerated mRNA degradation. PLoS
Pathog 10:e1003882. https://doi.org/10.1371/journal.ppat.1003882.
50. Abt M, de Jonge J, Laue M, Wolff T. 2011. Improvement of H5N1
influenza vaccine viruses: influence of internal gene segments of avian
and human origin on production and hemagglutinin content. Vaccine
29:5153–5162. https://doi.org/10.1016/j.vaccine.2011.05.036.
51. Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG. 2008.
Quantitation of haemagglutinin in H5N1 influenza viruses reveals low
haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 26:
6550–6554. https://doi.org/10.1016/j.vaccine.2008.09.050.
52. Kamal RP, Alymova IV, York IA. 2017. Evolution and virulence of influenza
A virus protein PB1-F2. Int J Mol Sci 19:96. https://doi.org/10.3390/
ijms19010096.
53. Khaperskyy DA, Emara MM, Johnston BP, Anderson P, Hatchette TF,
McCormick C. 2014. Influenza a virus host shutoff disables antiviral
stress-induced translation arrest. PLoS Pathog 10:e1004217. https://doi
.org/10.1371/journal.ppat.1004217.
54. Newton AH, Cardani A, Braciale TJ. 2016. The host immune response in
respiratory virus infection: balancing virus clearance and immunopathol-
ogy. Semin Immunopathol 38:471–482. https://doi.org/10.1007/s00281
-016-0558-0.
55. Klenk HD, Garten W, Matrosovich M. 2011. Molecular mechanisms of
interspecies transmission and pathogenicity of influenza viruses: Lessons
from the 2009 pandemic. Bioessays 33:180–188. https://doi.org/10
.1002/bies.201000118.
56. Baigent SJ, McCauley JW. 2003. Influenza type A in humans, mammals
and birds: determinants of virus virulence, host-range and interspecies
transmission. Bioessays 25:657–671. https://doi.org/10.1002/bies.10303.
57. Benton DJ, Martin SR, Wharton SA, McCauley JW. 2015. Biophysical
measurement of the balance of influenza a hemagglutinin and neur-
aminidase activities. J Biol Chem 290:6516–6521. https://doi.org/10
.1074/jbc.M114.622308.
58. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. 2003.
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases
influenza virus sensitivity to neuraminidase inhibitors. J Virol 77:
8418–8425. https://doi.org/10.1128/JVI.77.15.8418-8425.2003.
59. Moscovici C, Moscovici MG, Jimenez H, Lai MM, Hayman MJ, Vogt PK.
1977. Continuous tissue culture cell lines derived from chemically in-
duced tumors of Japanese quail. Cell 11:95–103. https://doi.org/10.1016/
0092-8674(77)90320-8.
60. de Wit E, Spronken MI, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD,
Fouchier RA. 2004. Efficient generation and growth of influenza virus
A/PR/8/34 from eight cDNA fragments. Virus Res 103:155–161. https://
doi.org/10.1016/j.virusres.2004.02.028.
61. Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. 2011.
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resis-
tance neuraminidase mutation shows a small compromise in enzyme
activity and viral fitness. J Antimicrob Chemother 66:466–470. https://
doi.org/10.1093/jac/dkq486.
62. Howard W, Hayman A, Lackenby A, Whiteley A, Londt B, Banks J,
McCauley J, Barclay W. 2007. Development of a reverse genetics system
enabling the rescue of recombinant avian influenza virus A/Turkey/
England/50-92/91 (H5N1). Avian Dis 51:393–395. https://doi.org/10
.1637/7645-050906R1.1.
63. Turnbull ML, Wise HM, Nicol MQ, Smith N, Dunfee RL, Beard PM, Jagger
BW, Ligertwood Y, Hardisty GR, Xiao H, Benton DJ, Coburn AM, Paulo JA,
Gygi SP, McCauley JW, Taubenberger JK, Lycett SJ, Weekes MP, Dutia
BM, Digard P. 2016. Role of the B allele of influenza A virus segment 8
in setting mammalian host range and pathogenicity. J Virol 90:
9263–9284. https://doi.org/10.1128/JVI.01205-16.
64. Bourret V, Croville G, Mariette J, Klopp C, Bouchez O, Tiley L, Guérin J-L.
2013. Whole-genome, deep pyrosequencing analysis of a duck influenza
A virus evolution in swine cells. Infect Genet Evol 18:31–41. https://doi
.org/10.1016/j.meegid.2013.04.034.
65. Chen BJ, Leser GP, Jackson D, Lamb RA. 2008. The influenza virus M2
protein cytoplasmic tail interacts with the M1 protein and influences
virus assembly at the site of virus budding. J Virol 82:10059–10070.
https://doi.org/10.1128/JVI.01184-08.
66. Ping J, Dankar SK, Forbes NE, Keleta L, Zhou Y, Tyler S, Brown EG. 2010.
PB2 and hemagglutinin mutations are major determinants of host range
and virulence in mouse-adapted influenza A virus. J Virol 84:
10606–10618. https://doi.org/10.1128/JVI.01187-10.
67. Long JS, Giotis ES, Moncorge O, Frise R, Mistry B, James J, Morisson M,
Iqbal M, Vignal A, Skinner MA, Barclay WS. 2016. Species difference in
ANP32A underlies influenza A virus polymerase host restriction. Nature
529:101–104. https://doi.org/10.1038/nature16474.
68. Robertson JS, Engelhardt OG. 2010. Developing vaccines to combat pan-
demic influenza. Viruses 2:532–546. https://doi.org/10.3390/v2020532.
69. Noton SL, Medcalf E, Fisher D, Mullin AE, Elton D, Digard P. 2007.
Identification of the domains of the influenza A virus M1 matrix protein
Hussain et al. Journal of Virology
January 2019 Volume 93 Issue 2 e01551-18 jvi.asm.org 18
 o
n
 January 8, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
required for NP binding, oligomerization and incorporation into virions.
J Gen Virol 88:2280–2290. https://doi.org/10.1099/vir.0.82809-0.
70. Blok V, Cianci C, Tibbles KW, Inglis SC, Krystal M, Digard P. 1996.
Inhibition of the influenza virus RNA-dependent RNA polymerase by
antisera directed against the carboxy-terminal region of the PB2
subunit. J Gen Virol 77:1025–1033. https://doi.org/10.1099/0022-1317
-77-5-1025.
71. Poole E, Elton D, Medcalf L, Digard P. 2004. Functional domains of the
influenza A virus PB2 protein: identification of NP- and PB1-binding sites.
Virology 321:120–133. https://doi.org/10.1016/j.virol.2003.12.022.
72. Klimov A, Balish A, Veguilla V, Sun H, Schiffer J, Lu X, Katz JM, Hancock
K. 2012. Influenza virus titration, antigenic characterization, and serolog-
ical methods for antibody detection. Methods Mol Biol 865:25–51.
https://doi.org/10.1007/978-1-61779-621-0_3.
Influenza a Virus PA-X and Pathogenicity in Hens’ Eggs Journal of Virology
January 2019 Volume 93 Issue 2 e01551-18 jvi.asm.org 19
 o
n
 January 8, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
